MacroGenics (MGNX) to Release Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is anticipated to post its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect MacroGenics to post earnings of ($0.54) per share and revenue of $34.17 million for the quarter.

MacroGenics Trading Down 2.0 %

NASDAQ:MGNX opened at $2.49 on Thursday. The firm has a market capitalization of $156.28 million, a price-to-earnings ratio of -1.58 and a beta of 2.02. MacroGenics has a 1-year low of $2.34 and a 1-year high of $21.88. The business’s fifty day moving average price is $3.01 and its 200 day moving average price is $3.36.

Wall Street Analysts Forecast Growth

MGNX has been the topic of a number of research analyst reports. StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a research report on Sunday, November 10th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a research report on Wednesday, November 6th. Finally, JMP Securities cut MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.63.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.